Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March Mar 3, 2023 04:01PM
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March Mar 3, 2023 04:01PM
Impel Neuropharma (IMPL) PT Lowered to $40 at Cowen Nov 14, 2022 10:41AM
Impel NeuroPharma Inc. (IMPL) Enters $100 Million Royalty and Debt Financing Agreement With Oaktree Mar 17, 2022 08:02AM
Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree Mar 17, 2022 08:00AM


Mar 17, 2022 08:00AM Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree
Feb 28, 2022 08:00AM Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
Feb 28, 2022 08:00AM Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
Nov 15, 2021 08:00AM Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 15, 2021 08:00AM Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Sep 10, 2021 05:53AM Impel NeuroPharma Inc. (IMPL) Prices 3M Share Offering at $15/sh
Sep 9, 2021 08:00PM Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
Sep 9, 2021 08:00PM Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
Sep 7, 2021 04:01PM Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed Offering
Sep 7, 2021 04:01PM Impel NeuroPharma Announces Launch of Proposed Public Offering
Sep 7, 2021 04:01PM Impel NeuroPharma Announces Launch of Proposed Public Offering
Sep 3, 2021 10:57AM Impel Neuropharma (IMPL) PT Raised to $55 at Cowen on FDA Approval
Jul 7, 2021 08:05AM Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank
May 18, 2021 05:37AM UPDATE: Cowen Starts Impel Neuropharma (IMPL) at Outperform (correction)
Apr 23, 2021 11:51AM Impel NeuroPharma (IMPL) IPO Opens 2% Higher
Apr 23, 2021 05:46AM Impel NeuroPharma Inc. (IMPL) Prices 5.33M Share IPO at $15/Sh
Apr 22, 2021 06:48PM Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering